CLINICAL TRIAL MANAGEMENT & REGULATORY AFFAIRS in Pharma, Biotech, Medtech Domains



Similar documents
Regulatory strategies for small companies /SMEs

EU PAS Register Guide

EUROPEAN INDUSTRIAL PHARMACISTS GROUP

Emerging Device Topics for Regulatory Consideration.. Janine Jamieson May 2015

Regulatory approval routes in the European System for Medicinal Products

Overview. Health Science Authority. Implementation of ICH guideline in Singapore. Singapore s experience

EMA Update Clinical Trials

The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010

Risk management plans an overview

The European regulatory system for medicines and the European Medicines Agency

End of consultation (deadline for comments) 14 October Adoption by Committee for advanced therapies 15 October 2010

HTA and Post-Launch Studies

BIO-PARTNERING EUROPE EVENT SPEECH PAOLA TESTORI COGGI DIRECTOR GENERAL FOR HEALTH AND CONSUMERS EUROPEAN COMMISSION

PEDIATRIC MEDICINES: GLOBAL MARKETS

European Forum for Good Clinical Practice. 26 November Management Centre Europe, Brussels, Belgium. Children s Medicines Working Party

Questions and answers on post approval change management protocols

Implementation strategy for ISO IDMP in EU

How To Understand The Paediatric Regulation

The Product Review Life Cycle A Brief Overview

PRINCIPLES AND PRACTICES OF MEDICAL DEVICE DEVELOPMENT

White Paper The EU Clinical Trials Regulation Main Changes and Challenges

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Marketing Authorization Procedures in the European Union Making the Right Choice

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

THE BIOTECH & PHARMACEUTICAL INDUSTRY

Quality and Clinical Director

Our name ASPHALION derives from the Greek word asphaléia, alluding to values such as firmness, stability, certainty and reliability.

GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)

Strategy and pilot phase for patient registries

Post-authorisation safety studies and the EU PAS Register

A clinical research organization

The registry of the future: Leveraging EHR and patient data to drive better outcomes

Biotech Concerto #3. European Clinical Trial Environment

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP

Agence fédérale des médicaments et des produits de santé

training programme in pharmaceutical medicine Regulatory affairs

Importing pharmaceutical products to China

EUROPEAN MEDICINES PRACTICES AND TOOLS AGENCY DRUG SAFETY

Elements for optimising Orphan drug development industry perspective

Quick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal products

Project Management. Dissemination and Exploitation Services in Horizon 2020

Clinical trials in haemophilia

Cytel au service des maladies rares : exemple d un partenariat réussi

JSA in Germany with BfArM/PEI and G-BA

The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly

The majority of pharmaceutical companies in

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services

HTA NETWORK MULTIANNUAL WORK PROGRAMME

The Medical Device Industry in Korea: Strategies for Market Entry

Emergence of Compassionate Use programmes

Clinical trials in developing countries submitted to EMEA for regulatory purposes

Clinical Data for Medical Devices

European Commission Contract no. FIF : Users Guide to European Regulation in Biotechnology. Final Report, Part I: Complete text

Guideline on good pharmacovigilance practices (GVP)

Programme Specification

The Changing Regulatory Requirements for Applied Human Pharmacology. Thomas Sudhop Federal Institute for Drugs and Medical Devices (BfArM)

NSF-DBA Medical Device Diploma. Learning through doing with experts at your side

Guideline on good pharmacovigilance practices (GVP)

Questions & answers on signal management

Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices

The EMA current activities towards ISO IDMP implementation

Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC

Life Sciences & Healthcare

Aim of today s meeting/teleconference

Driving improved access to treatment via Europe and through national MS Societies

Report from the CMDh meeting held on September !!! 3 months to go until the mandatory use of the electronic application form!!!

Questions and answers on post approval change management protocols

Bundesinstitut für Arzneimittel und Medizinprodukte Step-by-step Guide on e-only Submission at BfArM

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research

How To Understand And Understand Biosimilars

Pediatric Research Networks A Plan for a Collaboration in Europe. Daniela Gunz Head Clinical Trial Operations Switzerland June 9, 2011

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)

SPEAKER BIOGRAPHICAL INFORMATION

Clinical Trial Data Sharing

Quality by Design Concept

RAPS ONLINE UNIVERSITY

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

EMA policy on publication of Clinical Data. SFdS - Journée Annuelle du groupe Biopharmacie & Santé

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

Benefits and Challenges of Change Protocol Approach: An EU Agency Perspective

EU Clinical Trials Register. An agency of the European Union

Pharmaceutical Quality & Clinical Research Quality: The Interaction

ALL Medical Devices regardless of Classification

Marketing Authorisation: The Evaluation Process

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

Clinical research: where are we with the new (Paediatric) RC trial Regulation

Orphan Drugs & Personalised Medicine: The Patient Perspective

Molecular Biotechnology Master s Degree Program

Fostering Further Collaboration between PMDA and Applicants with Efficient Project Management in Drug Development

Orphan Pharma: pathfinders for an increasingly specialised industry

Overview of Authorisation Procedures for Medicinal Products

How to search the EU Clinical Trials Register

Türkiye İlaç ve Tıbbi Cihaz Kurumu

Sarah Chandler A/Head, Regulatory and Scientific Section Medical Devices Bureau

Achievement of Korea s Healthcare Industry. Devices. World s largest market share in ultrasound imaging devices ( 14) Competitiveness

Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes

Key considerations for outsourcing late phase clinical research

Transcription:

CLINICAL TRIAL MANAGEMENT & REGULATORY AFFAIRS in Pharma, Biotech, Medtech Domains April 28-30, 2015 EPFL Quartier de l Innovation, Bâtiment E, 1st floor Module Leaders Christelle Bouygues, Regulatory Affairs Officer, Regulatory Affairs Office, Regulatory, Science and Innovation Support Department, at the European Medicines Agency, EMA, London Eric Klasen, VP Regulatory Affairs & Quality, Europe & Emerging Markets, Medtronic (Medtech track) & Team Andrew Galazka, Senior VP Global Medical Affairs, Merck Serono, Aubonne (Biotech-Pharma track) Marie Mellody & Angela Piazzi, Founders & Managing Directors, Virtuoso Sarl and Inovaclin Sarl (Biotech-Pharma track) Objectives To develop understanding and competencies in planning, conduct and management of clinical trials, in good practices, regulations and approvals by addressing topics such as: Clinical Research & Product Development Pharma, Biotech and Medtech The Clinical Trial process concept to conclusion and the management of the key operational challenges Pharmaceuticals and Medical Devices in the world more particularly in Europe and Switzerland Legislative framework and procedures Marketing authorization applications and approvals Activities under national responsibilities (pricing, reimbursement, advertising, follow up of medicines sales) New emerging therapies (cell therapy, gene therapy, etc) Overview The topics mentioned above will be addressed both from the view of a Regulatory agency and from the Pharma, Biotech and Medtech perspectives. It will be illustrated with real examples. After a first common morning on Regulatory Affairs Tuesday, there will be two tracks, either Biotech-Pharma track or Medtech track. (Participants have to choose in advance which tack they wish to follow). Evaluation Participants will be evaluated according to their answers to comprehensive multiple choice questionnaires.

Clinical Trial Management & Regulatory Affairs Tue 28.04.2015 9:15-12:45 Christelle Bouygues, Regulatory Affairs Officer The European Medicines Agency EMA, London 1) The European system for medicinal products, 2) New incentives to Pharmaceutical Development SME; Orphans; Scientific Advice; Protocol Assistance; Paediatric Medicines; Advanced Therapies 3) Trends in European Submissions Trends in EU Marketing Authorisation ; Generic/Hybrid/Biosimilar medicinal products ; Non-prescription medicinal products 4) Post-authorisation activities: Concepts of grouping, work sharing, new classification introduced since January 2010 resulting from the new Variation Regulation EC/1234/2008.Other post-authorisation procedures (PSUR, renewal, etc) 5) Influence of HTA on Regulatory Decision making Lunch 12:45 14:15

Clinical Trial Management & Regulatory Affairs Medtech track Tue 28.04.2015 14:15-15:15 Eric Klasen Vice President, Regulatory Affairs & Quality Medtronic Int l Trading sàrl Introduction to MedTech 16:00-17:45 Andrea Sparti Regulatory Affairs Manager, Medtronic Int l Trading s4rl Pre-Market Part I - Classification & Exercise Pre-Market Part II - Tech file & Design dossier - Conformity Assessment Routes - Standards - Post-Market Surveillance 09:15-12:30 Danielle Giroud Founder WMDO Clinical Evidence for Medical Devices - Global Clinical Strategy - Clinical Evaluation - Clinical Study Design for Market Access - Clinical Study management You will be asked to make a 5-10 minutes presentation on your approach to clinical development Maura Arsiero, PhD Case Study: Second Sight 14:15-17:30 Country Manager Second Sight Medical Products Sàrl

Clinical Trial Management & Regulatory Affairs Medtech track 9:15-12:30 Benedict Brown Reimbursement Director Medtronic Int l Trading sàrl Market access for medical devices Reimbursement and Health Technology Assessment 12:45 14:15 Lunch 14:15-15:00 Matthias Buerger Vice President Quality Assurance & Regulatory Affairs Zimmer GmbH Introduction to Orthopedics and the Case Study 15:00-16:00 Breakout groups 16:00-16:45 Feedback discussion 17:00-17:15 Participants Evaluation Multiple choice questionnaire 17:15-17:30 Eric Klasen Wrap-up

Clinical Trial Management & Regulatory Affairs Biotech - Pharma track Tue 28.04.2015 14:15-16:45 Marie Mellody Managing Director, Virtuoso The Clinical Development Process Overview late phases of development and life cycle management Read in advance A Vision for the Future Genomics Prepare case studies in teams based on prereading of current considerations in drug development 16:45 17.45 Participants Team break-out discussions and presentations back to the group 09:15-12:45 Angela Piazzi Managing Director, Virtuoso The Current Environment for Clinical Operations and the Clinical Trial Operations Overview Team break-out discussions on clinical operations issues and presentations back to the group

Clinical Trial Management & Regulatory Affairs Biotech - Pharma track 14:15-17.45 Andrew Galazka Senior VP Global Medical Affairs, Merck Serono Case Studies: Examples of Product Development from the world of Biotechnology Part I Group discussion and interaction 09:15-12.45 Andrew Galazka Senior VP Global Medical Affairs, Merck Serono Case study and drug development discussion Part II Group discussion and interaction 12:45 14:15 Lunch 14:15-16.45 Andrew Galazka Senior VP Global Medical Affairs, Merck Serono Case study and drug development discussion Part III Group discussion and interaction 17:00-17:30 Participants Evaluation Pharma Track Multiple choice questionnaire

Clinical Trial Management & Regulatory Affairs Course material Day 1, 2 & 3 Medtech Track Interim Results from the International Trial of Second Sight s Visual Prosthesis, by Mark S. Humayun et al. 2011 by the American Academy of Ophthalmology Day 1, 2 & 3 Biotech-Pharma Track A Vision for the Future Genomics Lecturers presentations, articles, case studies and other documents will also be provided during class for both the Medtech and Biotech Track.